Cilostazol for prevention of recurrent stroke (clarity)
Ended Cooperative Agreement Awarded Last action
- Award ID
- UG3NS133209
- Recipient
-
The Leland Stanford Junior University UEI HJD6G4D6TJY5
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $17,243,103
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date
- Place of performance
- Palo Alto, CA 94304, USA
Award details come from USAspending.gov.
Description
- Abstract
- In recent years, clinical trials have demonstrated that ischemic stroke recurrence can be reduced during the first weeks after stroke or TIA with a short course of dual antiplatelet therapy (dapt). These trials, however, do not address the ongoing risk of recurrent stroke in the following years. Antiplatelet monotherapy with either aspirin or clopidogrel remains standard-of-care for long-term secondary stroke prevention in patients with non- cardioembolic stroke or TIA. On this regimen, the annual rate of major cardiovascular events (mace), predominantly recurrent stroke, averages 4-8%, highlighting the need for better long-term stroke prevention. A large trial of stroke prevention in japan suggested that long-term use of cilostazol cuts the risk of recurrent stroke and cardiovascular events (mace) in half, likely through beneficial pleiotropic effects on platelet aggregation, blood pressure, plasma lipids, and vascular remodeling. Despite this robust effect, cilostazol is rarely prescribed in the united states for secondary stroke prevention (
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $5,747,701 | |
| Amendment | $5,747,701 | |
| Original award | $5,747,701 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| The Medical University Of South Carolina | $205,748 | |
| Biomedical Research Institute Of New Mexico | $818,919 | |
| Cincinnati Univ Of | $1,594,958 | |
| The Medical University Of South Carolina | $736,499 | |
| Yale Univ | $375,324 |
Quick answers
Who received award UG3NS133209?
UG3NS133209 was awarded to The Leland Stanford Junior University by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on August 13, 2025.
How much is award UG3NS133209 worth?
$17,243,103 has been obligated on UG3NS133209.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award